We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various compo... Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. Show more
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2...
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass., Oct. 3, 2024 CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship...
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2 | 2.69179004038 | 7.43 | 8.09 | 6.94 | 119412 | 7.53624508 | CS |
4 | -1.42 | -15.6906077348 | 9.05 | 10.25 | 6.94 | 229850 | 9.20520828 | CS |
12 | 1.56 | 25.7001647446 | 6.07 | 10.25 | 4.87 | 155864 | 8.33931683 | CS |
26 | 0.47 | 6.56424581006 | 7.16 | 10.25 | 4.77 | 122615 | 7.30648901 | CS |
52 | 3.86 | 102.387267905 | 3.77 | 10.25 | 2.7 | 125232 | 6.17749197 | CS |
156 | -5.59 | -42.2844175492 | 13.22 | 24.34 | 2.7 | 147751 | 11.50265742 | CS |
260 | -10.49 | -57.8918322296 | 18.12 | 28.265 | 2.7 | 139691 | 12.20319566 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions